Popular Weight-Loss Drug May Cut Heart Attack Risk by 54%, New Studies Find

New research on tirzepatide, the drug behind Zepbound and Mounjaro, suggests it could significantly lower the risk of major cardiovascular event.

BY LEILA SHERIDAN, NEWS WRITER

Illustration: Inc; Photo: Getty Images

Tirzepatide, the drug behind blockbuster treatments like Zepbound and Mounjaro, is best known for driving significant weight loss. But new research suggests its benefits may extend well beyond the scale, potentially lowering the risk of some of the deadliest heart complications.

In two recent studies of high-risk patients undergoing major cardiac........

© Inc.com